HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Clinical study of the French cohort of Gaucher disease patients].

Abstract
A census is currently being carried out of the French cohort of Gaucher disease patients. This article describes its preliminary results, obtained by analysing the records of 101 patients for whom clinical and laboratory data were accessible while they were receiving enzyme therapy. At the time of diagnosis, all patients presented with splenomegaly, 70% had asthenia and one in three was already affected by major bone damage. After 1 year of enzyme therapy, splenomegaly had diminished by half and the different scores (asthenia, bone pain and abdominal pain, etc.) had markedly improved, as had the biochemical markers. As for the 6 patients affected by type 3 Gaucher disease and treated with enzyme therapy after the onset of neurological signs, a stabilisation or even some improvement of the disease was observed. In-depth study of the French cohort should make it possible to formulate consensus recommendations for the future, based on well-established data.
AuthorsJ Stirnemann
JournalLa Revue de medecine interne (Rev Med Interne) Vol. 27 Suppl 1 Pg. S18-21 (Mar 2006) ISSN: 0248-8663 [Print] France
Vernacular TitleEtude clinique de la cohorte française de patients atteints de la maladie de Gaucher.
PMID16644396 (Publication Type: Clinical Trial, Comparative Study, Journal Article)
Chemical References
  • Biomarkers
  • Enzyme Inhibitors
  • Recombinant Proteins
  • 1-Deoxynojirimycin
  • miglustat
  • Glucosylceramidase
  • imiglucerase
Topics
  • 1-Deoxynojirimycin (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Asthenia (etiology)
  • Biomarkers
  • Child
  • Child, Preschool
  • Cohort Studies
  • Enzyme Inhibitors (administration & dosage, therapeutic use)
  • Follow-Up Studies
  • Forecasting
  • France (epidemiology)
  • Gaucher Disease (classification, complications, drug therapy, epidemiology)
  • Glucosylceramidase (administration & dosage, adverse effects, therapeutic use)
  • Humans
  • Infant
  • Infant, Newborn
  • Middle Aged
  • Recombinant Proteins (administration & dosage, therapeutic use)
  • Splenectomy
  • Splenomegaly (etiology, surgery)
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: